Aether Industries Limited has announced its unaudited financial results for the third quarter ended December 31, 2025, delivering strong performance across key financial metrics while providing strategic guidance for future capacity utilization and updated revenue projections. The specialty chemicals manufacturer reported consolidated net profit of ₹644.79 million compared to ₹433.90 million in the corresponding quarter of the previous year, representing a substantial year-on-year growth of 49%.

Strong Revenue and Operational Performance

The company achieved impressive revenue growth with consolidated revenue from operations reaching ₹3,171.21 million compared to ₹2,196.81 million in Q3FY25, marking a robust year-on-year growth of 44.4%. The company's operational efficiency improved significantly, with profit before exceptional items and tax rising to ₹895.12 million from ₹640.83 million in the previous year.

Strategic Revenue Mix and Sector Growth Outlook

Aether Industries has outlined its strategic revenue composition targets, aiming for 70% of revenue to come from Contract Research and Manufacturing Services (CRAMS) and Contract Engineering and Manufacturing (CEM), while 30% will be derived from large-scale manufacturing operations. The company expects growth in oil, gas, and material science sectors by the end of the year, positioning itself strategically across these high-growth industrial segments.

Updated Revenue Guidance and EBITDA Margin Outlook

Aether Industries has provided updated guidance on its revenue expectations and margin sustainability. The company expects sales of ₹35 to 40 crores from its contract with Otsuka Chemicals for FY2026. Additionally, the company has issued sustainable EBITDA margin guidance of 29% to 30%, noting that the Q3 FY2026 margin of 34% was enhanced by a one-time claim.

Site-Wise Sales Outlook and Product Performance

The company has provided specific guidance on its facility-wise performance expectations. Sales from Site-4 are expected to remain steady for FY2026, with growth anticipated for FY2027. This strategic outlook reflects the company's measured approach to capacity expansion and market development across its manufacturing facilities.

Future Capacity Utilization and Strategic Outlook

Aether Industries has provided guidance on its capacity utilization expectations for FY2027. The company expects Site-3++ capacity utilization to be between 45% and 50% for FY2027, while initial blocks of Site-5 will likely reach 35% to 40%. Converge Polyol sales are set to meet FY2026 goals, and rising customer inquiries give management confidence for FY2027 performance.

R&D Pipeline and Contract Development

The company has highlighted significant developments in its research and development pipeline. Three to four molecules from the R&D pipeline, similar in size to the Miliken Contract, are anticipated to generate major contracts within one to three years. This development underscores the company's strong innovation capabilities and potential for sustained growth through new product commercialization. The Miliken Contract is set to start commercialization in Q1 FY2027, marking a significant milestone for the company's contract manufacturing business.

Nine-Month Performance Highlights

For the nine months ended December 31, 2025, the company maintained its growth momentum with consolidated net profit reaching ₹1,654.56 million compared to ₹1,081.23 million in the corresponding period of the previous year, representing a growth of 53%. Revenue from operations for the nine-month period stood at ₹8,533.58 million against ₹5,984.94 million in the previous year, showing a growth of 42.6%.

Earnings Call Audio Recording Available

In compliance with SEBI regulations, Aether Industries Limited has made available the audio recording of its earnings conference call for Q3FY26 results held on February 3, 2026. The recording is accessible on the company's official website and provides detailed discussions on the financial performance for the quarter and nine months ended December 31, 2025.

Aether Industries Limited has announced the allotment of 13,948 equity shares under its Employee Stock Option Scheme (ESOS) 2021, as approved by the Nomination and Remuneration Committee. This latest employee ownership initiative demonstrates the company's continued commitment to aligning employee interests with corporate growth objectives.

Latest Allotment Details

The company's regulatory filing reveals the specifics of this share allotment:

Updated Share Capital Structure

Following this allotment, Aether Industries' share capital structure has been updated:

The newly issued shares will rank pari-passu with existing equity shares, providing equal rights and privileges to the beneficiaries.

ESOS 2021 Framework

Aether Industries' Employee Stock Option Scheme 2021 operates under regulatory approvals from major stock exchanges. The scheme has received in-principle approval for a total pool of 11,00,000 equity shares from both BSE Limited and National Stock Exchange of India Limited.

Regulatory Compliance and Next Steps

The company has fulfilled all regulatory requirements for this allotment. Aether Industries will communicate this corporate action to depositories for crediting shares to beneficiaries' accounts, followed by obtaining listing and trading approvals from stock exchanges. The company has already paid listing fees for issued share capital up to Rs. 200 crores for the current fiscal year, requiring no additional exchange fees.

Strategic Implications

This employee stock option allotment reinforces Aether Industries' strategy of enhancing employee engagement and retention in the competitive specialty chemicals sector. By providing equity participation opportunities, the company aims to strengthen its human capital foundation while fostering long-term employee commitment to organizational success.